Relay Therapeutics plans to initiate ReDiscover-2, a Phase 3 trial evaluating RLY-2608 plus fulvestrant in PI3Kα-mutated, HR+/HER2- advanced breast cancer patients, with enrollment target of 540 patients.
Rallybio is set to begin a Phase 2 trial for RLYB212 in Q2 2025, targeting Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) prevention, with interim data expected in Q3.
Rallybio has dosed the first participant in a Phase II trial of RLYB212, a potential treatment for fetal and neonatal alloimmune thrombocytopenia (FNAIT).
Rallybio has received CTA approvals for its RLYB212 Phase 2 clinical trial, with screening of pregnant women at higher risk for FNAIT expected to begin in Q4 2024.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.